IL6 and neoplasm: In addition, studies in breast cancer patient-derived xenografts (PDX) have also shown that IL-6 and IL-8 release by CD10+ GPR77+ CAFs increases cancer stem cell activity via persistent activation of NF-κB to support tumor survival and chemotherapy resistance [163].